Deficiency of programmed cell death 4 results in increased IL-10 expression by macrophages and thereby attenuates atherosclerosis in hyperlipidemic mice

Cellular and Molecular Immunology

Volumn 13, Issue 4, 2016, Pages 524-534

  Jiang, Yang ^a   Gao, Qi ^a   Wang, Liyang ^a   Guo, Chun ^a   Zhu, Faliang ^a   Wang, Bo ^a   Wang, Qun ^a   Gao, Fei ^b   Chen, Youhai ^c   Zhang, Lining ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Atherosclerosis; IL 10; macrophage; Pdcd4

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 17; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; NEUTRALIZING ANTIBODY; PROGRAMMED CELL DEATH 4; PROTEIN; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; APOPTOSIS REGULATORY PROTEIN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PDCD4 PROTEIN, MOUSE; RECOMBINANT PROTEIN; RNA BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DRUG TARGETING; GENE INACTIVATION; GENETIC TRANSCRIPTION; HYPERLIPIDEMIA; IN VITRO STUDY; INFLAMMATORY DISEASE; LIPID DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROTEIN DEFECT; PROTEIN EXPRESSION; RNA TRANSLATION; T LYMPHOCYTE; UPREGULATION; ANIMAL; C57BL MOUSE; DEFICIENCY; DRUG EFFECTS; FEMALE; METABOLISM; PATHOLOGY; PERITONEUM MACROPHAGE; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, NEUTRALIZING; APOLIPOPROTEINS E; APOPTOSIS REGULATORY PROTEINS; ATHEROSCLEROSIS; FEMALE; HYPERLIPIDEMIAS; INTERLEUKIN-10; INTERLEUKIN-17; LIPOPROTEINS, LDL; MACROPHAGES, PERITONEAL; MALE; MAP KINASE SIGNALING SYSTEM; MICE, INBRED C57BL; PLAQUE, ATHEROSCLEROTIC; RECOMBINANT PROTEINS; RNA-BINDING PROTEINS; T-LYMPHOCYTES;

EID: 84977495034     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2015.47     Document Type: Article

References (44)

1. Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S et al. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol 2003; 23: 26-37.
2. Shibahara K, Asano M, Ishida Y, Aoki T, Koike T, Honjo T. Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene 1995; 166: 297-301.
3. Singh P, Wedeken L, Waters LC, Carr MD, Klempnauer KH. Pdcd4 directly binds the coding region of c-myb mRNA and suppresses its translation. Oncogene 2011; 30: 4864-4873.
4. Wang Q, Sun Z, Yang HS. Downregulation of tumor suppressor Pdcd4 promotes invasion and activates both beta-catenin/Tcf and AP-1-dependent transcription in colon carcinoma cells. Oncogene 2008; 27: 1527-1535.
5. Waters LC, Veverka V, Bohm M, Schmedt T, Choong PT, Muskett FW et al. Structure of the C-terminal MA-3 domain of the tumour suppressor protein Pdcd4 and characterization of its interaction with eIF4A. Oncogene 2007; 26: 4941-4950.
6. Chen Y, Knosel T, Kristiansen G, Pietas A, Garber ME, Matsuhashi S et al. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol 2003; 200: 640-646.
7. Mudduluru G, Medved F, Grobholz R, Jost C, Gruber A, Leupold JH et al. Loss of programmed cell death 4 expression marks adenomacarcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer 2007; 110: 1697-1707.
8. Gao F, Zhang P, Zhou C, Li J, Wang Q, Zhu F et al. Frequent loss of PDCD4 expression in human glioma: possible role in the tumorigenesis of glioma. Oncol Rep 2007; 17: 123-128.
9. Wei ZT, Zhang X, Wang XY, Gao F, Zhou CJ, Zhu FL et al. PDCD4 inhibits the malignant phenotype of ovarian cancer cells. Cancer Sci 2009; 100: 1408-1413.
10. Zhang X, Wang X, Song X, Liu C, Shi Y, Wang Y et al. Programmed cell death 4 enhances chemosensitivity of ovarian cancer cells by activating death receptor pathway in vitro and in vivo. Cancer Sci 2010; 101: 2163-2170.
11. Hilliard A, Hilliard B, Zheng SJ, Sun H, Miwa T, Song W et al. Translational regulation of autoimmune inflammation and lymphoma genesis by programmed cell death 4. J Immunol 2006; 177: 8095-8102.
12. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O'Leary JJ, Ruan Q et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010; 11: 141-147.
13. Ruan Q, Wang T, Kameswaran V, Wei Q, Johnson DS, Matschinsky F et al. The microRNA-21-PDCD4 axis prevents type 1 diabetes by blocking pancreatic beta cell death. Proc Natl Acad Sci USA 2011; 108: 12030-12035.
14. Wang Q, Dong Z, Liu X, Song X, Song Q, Shang Q et al. Programmed cell death-4 deficiency prevents diet-induced obesity, adipose tissue inflammation, and insulin resistance. Diabetes 2013; 62: 4132-4143.
15. Zhong B, Yang X, Sun Q, Liu L, Lan X, Tian J et al. Pdcd4 modulates markers of macrophage alternative activation and airway remodeling in antigen-induced pulmonary inflammation. J Leukoc Biol 2014; 96: 1065-1075.
16. Wang X, Zhang L, Wei Z, Zhang X, Gao Q, Ma Y et al. The inhibitory action of PDCD4 in lipopolysaccharide/D-galactosamine-induced acute liver injury. Lab Invest 2013; 93: 291-302.
17. Di Tullio MR, Russo C, Jin Z, Sacco RL, Mohr JP, Homma S et al. Aortic arch plaques and risk of recurrent stroke and death. Circulation 2009; 119: 2376-2382.
18. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
19. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011; 145: 341-355.
20. Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res 2001; 88: 877-887.
21. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12: 204-212.
22. Huber SA, Sakkinen P, David C, Newell MK, Tracy RP. T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation 2001; 103: 2610-2616.
23. Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(1) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 2000; 102: 2919-2922.
24. Whitman SC, Ravisankar P, Elam H, Daugherty A. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E2/2 mice. Am J Pathol 2000; 157: 1819-1824.
25. Gao Q, Jiang Y, Ma T, Zhu F, Gao F, Zhang P et al. A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. J Immunol 2010; 185: 5820-5827.
26. Smith E, Prasad KM, Butcher M, Dobrian A, Kolls JK, Ley K et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 2010; 121: 1746-1755.
27. Groux H. Type 1 T-regulatory cells: their role in the control of immune responses. Transplantation 2003; 75: 8S-12S.
28. Halvorsen B, Waehre T, Scholz H, Clausen OP, von der Thusen JH, Muller F et al. Interleukin-10 enhances the oxidized LDL-induced foam cell formation of macrophages by antiapoptotic mechanisms. J Lipid Res 2005; 46: 211-219.
29. Arjuman A, Chandra NC. Effect of IL-10 on LOX-1 expression, signalling and functional activity: an atheroprotective response. Diab Vasc Dis Res 2013; 10: 442-451.
30. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: e17-e24.
31. Pinderski Oslund LJ, Hedrick CC, Olvera T, Hagenbaugh A, Territo M, Berliner JA et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999; 19: 2847-2853.
32. Almer G, Frascione D, Pali-Scholl I, Vonach C, Lukschal A, Stremnitzer C et al. Interleukin-10: an anti-inflammatory marker to target atherosclerotic lesions via PEGylated liposomes. Mol Pharm 2013; 10: 175-186.
33. Caligiuri G, Rudling M, Ollivier V, Jacob MP, Michel JB, Hansson GK et al. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med 2003; 9: 10-17.
34. Namiki M, Kawashima S, Yamashita T, Ozaki M, Sakoda T, Inoue N et al. Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice. Atherosclerosis 2004; 172: 21-29.
35. Das A, Ganesh K, Khanna S, Sen CK, Roy S. Engulfment of apoptotic cells by macrophages: a role of microRNA-21 in the resolution of wound inflammation. J Immunol 2014; 192: 1120-1129.
36. van den Bosch MW, Palsson-Mcdermott E, Johnson DS, O'Neill LA. LPS induces the degradation of programmed cell death protein 4 (PDCD4) to release Twist2, activating c-Maf transcription to promote interleukin-10 production. J Biol Chem 2014; 289: 22980-22990.
37. Chi H, Barry SP, Roth RJ,WuJJ, Jones EA, BennettAMet al. Dynamic regulation of pro-and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci USA 2006; 103: 2274-2279.
38. Jansen AP, Camalier CE, Colburn NH. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res 2005; 65: 6034-6041.
39. Cheng Y, Liu X, Zhang S, Lin Y, Yang J, Zhang C. MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. J Mol Cell Cardiol 2009; 47: 5-14.
40. Cheng Y, Zhu P, Yang J, Liu X, Dong S, Wang X et al. Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4. Cardiovasc Res 2010; 87: 431-439.
41. Sii-Felice K, Pouponnot C, Gillet S, Lecoin L, Girault JA, Eychene A et al. MafA transcription factor is phosphorylated by p38 MAP kinase. FEBS Lett 2005; 579: 3547-3554.
42. Benkhelifa S, Provot S, Nabais E, Eychene A, Calothy G, Felder-Schmittbuhl MP. Phosphorylation of MafA is essential for its transcriptional and biological properties. Mol Cell Biol 2001; 21: 4441-4452.
43. Taleb S, Tedgui A, Mallat Z. Interleukin-17: friend or foe in atherosclerosis? Curr Opin Lipidol 2010; 21: 404-408.
44. Yu XH, Jiang N, Zheng XL, Cayabyab FS, Tang ZB, Tang CK. Interleukin-17A in lipid metabolism and atherosclerosis. Clin Chim Acta 2014; 431: 33-39.